Published in Mov Disord on October 30, 2010
New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry (2011) 2.11
Susceptibility to a parkinsonian toxin varies during primate development. Exp Neurol (2012) 1.41
Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin (2011) 0.96
Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci (2013) 0.95
Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One (2012) 0.92
Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease. Neuroscience (2011) 0.90
Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol (2012) 0.89
Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction. Neuroreport (2011) 0.88
SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Exp Neurol (2013) 0.88
Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am (2013) 0.87
Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat. Psychopharmacology (Berl) (2011) 0.87
Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain. PLoS One (2011) 0.86
SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Exp Neurol (2014) 0.86
Methamphetamine and Parkinson's disease. Parkinsons Dis (2013) 0.86
Glial reactivity in resistance to methamphetamine-induced neurotoxicity. J Neurochem (2013) 0.85
Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology (2012) 0.83
Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One (2013) 0.83
Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol (2015) 0.82
Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish national cohort study 1972-2008. BMC Neurol (2013) 0.81
Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects. Am J Drug Alcohol Abuse (2015) 0.81
Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. Exp Neurol (2013) 0.79
Illicit stimulant use in humans is associated with a long-term increase in tremor. PLoS One (2012) 0.78
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons. Neural Regen Res (2014) 0.78
Development of Parkinson's disease in patients with Narcolepsy. J Neural Transm (Vienna) (2012) 0.78
Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways. Psychopharmacology (Berl) (2016) 0.78
Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration? Neurotox Res (2013) 0.78
A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity. Neurosci Lett (2013) 0.77
Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits. J Pharmacol Exp Ther (2015) 0.76
Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK. J Neuroinflammation (2016) 0.76
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) (2014) 0.76
Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence. Eur J Neurosci (2016) 0.76
Hand function is altered in individuals with a history of illicit stimulant use. PLoS One (2014) 0.76
Evaluating the role of neuronal nitric oxide synthase-containing striatal interneurons in methamphetamine-induced dopamine neurotoxicity. Neurotox Res (2013) 0.76
Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice. J Addict Prev (2015) 0.75
Exploration of Temporal ICD Coding Bias Related to Acute Diabetic Conditions. AMIA Annu Symp Proc (2015) 0.75
Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors. Behav Pharmacol (2016) 0.75
Current concepts in the diagnosis and management of Parkinson's disease. CMAJ (2003) 1.83
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord (2012) 1.44
Mitochondria in Alzheimer's disease. Int Rev Neurobiol (2002) 1.40
Why is parkinsonism not a feature of human methamphetamine users? Brain (2003) 1.29
Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem (2003) 1.28
Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend (2011) 1.25
The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction (2013) 1.15
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2013) 1.12
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry (2011) 1.09
Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry (2012) 1.09
Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther (2006) 1.07
Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse (2004) 1.05
Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology (2008) 1.01
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse (2008) 0.96
Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab (2012) 0.93
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord (2008) 0.93
The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging (2011) 0.93
Brain antioxidant systems in human methamphetamine users. J Neurochem (2004) 0.92
All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alcohol Depend (2012) 0.90
Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline. Arch Neurol (2006) 0.87
[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. Mov Disord (2015) 0.86
Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology (2007) 0.86
Does hyperthyroidism increase risk of death due to the ingestion of ecstasy? J Forensic Sci (2007) 0.86
Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens. J Neurochem (2007) 0.85
Guidelines for measuring impacts of methamphetamine precursor chemical regulations: a reply to Reuter and Caulkins (2003). Addiction (2003) 0.85
Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Ann Neurol (2002) 0.85
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord (2004) 0.84
See Me Smoke-Free: Protocol for a Research Study to Develop and Test the Feasibility of an mHealth App for Women to Address Smoking, Diet, and Physical Activity. JMIR Res Protoc (2016) 0.84
Predicting hospital length of stay for geriatric patients with mood disorders. Can J Psychiatry (2012) 0.83
Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse (2010) 0.83
Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. Drug Alcohol Depend (2009) 0.83
Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord (2003) 0.83
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2011) 0.83
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol (2013) 0.82
Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci (2004) 0.82
Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (2004) 0.81
Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol (2002) 0.81
Identification of a noradrenaline-rich subdivision of the human nucleus accumbens. J Neurochem (2005) 0.81
Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine. Drug Alcohol Depend (2002) 0.81
Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend (2011) 0.81
Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol Dis (2010) 0.80
Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry (2003) 0.80
Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord (2006) 0.79
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. J Cereb Blood Flow Metab (2011) 0.78
Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol (2012) 0.78
What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? Mov Disord (2003) 0.77
TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum. Brain Res (2009) 0.77
Trends in primary methamphetamine-related admissions to youth residential substance abuse treatment facilities in Canada, 2005-2006 and 2009-2010. Can J Psychiatry (2011) 0.76
Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol (2004) 0.76
Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet (2002) 0.75
Effects of the minimum legal drinking age on alcohol-related health service use in hospital settings in Ontario: a regression-discontinuity approach. Am J Public Health (2013) 0.75
Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications. Eur J Neurosci (2017) 0.75
Hazardous birthday drinking among young people: population-based impacts on emergency department and in-patient hospital admissions. Addiction (2014) 0.75
Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein alphas isoforms in postmortem bipolar affective disorder temporal cortex. J Neurosci Res (2003) 0.75
Takotsubo cardiomyopathy associated with lithium intoxication in bipolar disorder: a case report. J Clin Psychopharmacol (2014) 0.75